2761 - 2770 of 8399 Results
Title
Year
-
RESTRICTEDTitle: Multiplexed Profiling of Extracellular Vesicles for Biomarker DevelopmentJournal Name: Nano-Micro LettersPublisher: Springer Science and Business Media LLCVol: 14Issue #: 1Start Page:End Page:Publication Date:Open Access(OA) Status: RESTRICTEDLicense: cc-byDOI - Digital Object Identifier: 10.1007/s40820-021-00753-wBest OA location URL: https://link.springer.com/content/pdf/10.1007/s40820-021-00753-w.pdfCitation Count: 42
- Phase 2 Trial of Rituximab in Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis2021OPENTitle: Phase 2 Trial of Rituximab in Acetylcholine Receptor Antibody-Positive Generalized Myasthenia GravisJournal Name: NeurologyPublisher: Ovid Technologies (Wolters Kluwer Health)Vol: 98Issue #: 4Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1212/wnl.0000000000013121Best OA location URL: https://n.neurology.org/content/neurology/98/4/e376.full.pdfCitation Count: 86
-
OPENTitle: The contribution of behavioral features to caregiver burden in FTLD spectrum disordersJournal Name: Alzheimer's & DementiaPublisher: WileyVol: 18Issue #: 9Start Page: 1635End Page: 1649Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1002/alz.12494Best OA location URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9160199Citation Count: 22
-
RESTRICTEDTitle: A brief history of nearly EV‐erything – The rise and rise of extracellular vesiclesJournal Name: Journal of Extracellular VesiclesPublisher: WileyVol: 10Issue #: 14Start Page:End Page:Publication Date:Open Access(OA) Status: RESTRICTEDLicense: cc-byDOI - Digital Object Identifier: 10.1002/jev2.12144Best OA location URL: http://pure-oai.bham.ac.uk/ws/files/158007662/J_of_Extracellular_Vesicle_2021_Couch_A_brief_history_of_nearly_EV_erything_The_rise_and_rise_of_extracellular.pdfCitation Count: 176
-
RESTRICTEDTitle: Amantadine in the treatment of Parkinson's disease and other movement disordersJournal Name: The Lancet NeurologyPublisher: Elsevier BVVol: 20Issue #: 12Start Page: 1048End Page: 1056Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/s1474-4422(21)00249-0Citation Count: 73
-
RESTRICTEDTitle: Autophagy and the hallmarks of agingJournal Name: Ageing Research ReviewsPublisher: Elsevier BVVol: 72Issue #:Start Page: 101468End Page: 101468Publication Date:Open Access(OA) Status: RESTRICTEDLicense: publisher-specific-oaDOI - Digital Object Identifier: 10.1016/j.arr.2021.101468Best OA location URL: http://manuscript.elsevier.com/S1568163721002154/pdf/S1568163721002154.pdfCitation Count: 115
-
RESTRICTEDTitle: Corrigendum to “Anti-α-synuclein ASO delivered to monoamine neurons prevents α-synuclein accumulation in a Parkinson's disease-like mouse model and in monkeys” [EBioMedicine 2020; 59:102944]Journal Name: eBioMedicinePublisher: Elsevier BVVol: 74Issue #:Start Page: 103731End Page: 103731Publication Date:Open Access(OA) Status: RESTRICTEDLicense: cc-by-nc-ndDOI - Digital Object Identifier: 10.1016/j.ebiom.2021.103731Best OA location URL: http://www.thelancet.com/article/S2352396421005259/pdfCitation Count: 0
-
OPENTitle: Discrimination of MSA-P and MSA-C by RT-QuIC analysis of olfactory mucosa: the first assessment of assay reproducibility between two specialized laboratoriesJournal Name: Molecular NeurodegenerationPublisher: Springer Science and Business Media LLCVol: 16Issue #: 1Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1186/s13024-021-00491-yBest OA location URL: https://molecularneurodegeneration.biomedcentral.com/counter/pdf/10.1186/s13024-021-00491-yCitation Count: 45
-
RESTRICTEDTitle: Disease modifying therapies for Parkinson's disease: Novel targetsJournal Name: NeuropharmacologyPublisher: Elsevier BVVol: 201Issue #:Start Page: 108839End Page: 108839Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/j.neuropharm.2021.108839Citation Count: 4
-
OPENTitle: Engineering immunoproteasome-expressing mesenchymal stromal cells: A potent cellular vaccine for lymphoma and melanoma in miceJournal Name: Cell Reports MedicinePublisher: Elsevier BVVol: 2Issue #: 12Start Page: 100455End Page: 100455Publication Date:Open Access(OA) Status: OPENLicense: cc-by-nc-ndDOI - Digital Object Identifier: 10.1016/j.xcrm.2021.100455Best OA location URL: http://www.cell.com/article/S2666379121003232/pdfCitation Count: 25